ABBV
Allergan Aesthetics (NYSE: ABBV) partnered with New York-based entrepreneur and television personality Erin...
Article Summary
BUY- Allergan Aesthetics (NYSE: ABBV) partnered with New York-based entrepreneur and television personality Erin Lichy to promote transparency and normalize conversations around aesthetic procedures.
- Lichy is opening up about her recent breast augmentation with market-leading Natrelle® breast implants as part of her personal journey towards renewed body positivity, with the goal of supporting other women considering breast surgery.
- Abbvie will share Lichy's experience from consultation to post-op across social media channels and encourage patients to enter the Faces ofNatrelle Testimonial Program to share their personal experiences through photos, videos, and written testimonials for a chance to be featured on the brand's social media platforms and website.
- With the most comprehensive range of smooth breast implant options built on a 50-year legacy of innovation in breast aesthetics and offers five profiles and three gummy gel cohesivities, the brand continues to prioritize patient education and close partnership with board-certified plastic surgeons, with 10-year safety profile backed by rigorous clinical trial.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 8.6% | 25% | 35.0 ptsBelow Screener (8.6%) - Weak growth |
| EPS Growth Next 5Y ? | 21.4% | 25% | 70.0 ptsGood (21.4%) - Solid outlook |
| Target Price Upside ? | 23.4% | 20% | 70.0 ptsGood Upside (23.4%) - Target: $255.12 vs Current: $206.72 |
| Gross Margin % ? | 70.1% | 15% | 100.0 ptsExceptional (70.1%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -15.6% | 15% | 40.0 ptsMild Pullback (-15.6%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ABBV
- AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
- The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
- It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
- In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis.
- Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
- The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.